Research programme: wound healing agents - Chemokine

Drug Profile

Research programme: wound healing agents - Chemokine

Alternative Names: CTC-0422; CTCE 0422

Latest Information Update: 24 Jul 2007

Price : $50

At a glance

  • Originator Chemokine Therapeutics
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Preclinical Wounds

Most Recent Events

  • 24 Jul 2007 CTCE 0422 is still in preclinical development for wound healing in Canada
  • 07 Mar 2006 Preclinical trials in Wounds in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top